These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 9063474)

  • 1. [Reversal of drug resistance in human cancer cells by anti-oncogenes].
    Funato T
    Gan To Kagaku Ryoho; 1997 Feb; 24(4):395-400. PubMed ID: 9063474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Circumventing multidrug resistance in human cancer by anti-ribozyme].
    Funato T
    Nihon Rinsho; 1997 May; 55(5):1116-21. PubMed ID: 9155162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of cisplatin resistance in vivo by an anti-fos ribozyme.
    Funato T; Ishii T; Kanbe M; Scanlon KJ; Sasaki T
    In Vivo; 1997; 11(3):217-20. PubMed ID: 9239514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic applications of ribozymes.
    Kijima H; Ishida H; Ohkawa T; Kashani-Sabet M; Scanlon KJ
    Pharmacol Ther; 1995; 68(2):247-67. PubMed ID: 8719970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Circumventing drug resistance in human tumors by antisense ribozyme].
    Funato T
    Gan To Kagaku Ryoho; 1994 Feb; 21(3):336-42. PubMed ID: 8109989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of systemically delivered ribozymes targeting murine telomerase RNA.
    Nosrati M; Li S; Bagheri S; Ginzinger D; Blackburn EH; Debs RJ; Kashani-Sabet M
    Clin Cancer Res; 2004 Aug; 10(15):4983-90. PubMed ID: 15297398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming the classical multidrug resistance phenotype by adenoviral delivery of anti-MDR1 short hairpin RNAs and ribozymes.
    Kaszubiak A; Holm PS; Lage H
    Int J Oncol; 2007 Aug; 31(2):419-30. PubMed ID: 17611700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.
    Bonovich M; Olive M; Reed E; O'Connell B; Vinson C
    Cancer Gene Ther; 2002 Jan; 9(1):62-70. PubMed ID: 11916245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribozymes: applications to functional analysis and gene discovery.
    Shiota M; Sano M; Miyagishi M; Taira K
    J Biochem; 2004 Aug; 136(2):133-47. PubMed ID: 15496583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.
    Liu LZ; Zhou XD; Qian G; Shi X; Fang J; Jiang BH
    Cancer Res; 2007 Jul; 67(13):6325-32. PubMed ID: 17616691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene.
    Nagata J; Kijima H; Hatanaka H; Asai S; Miyachi H; Abe Y; Yamazaki H; Nakamura M; Watanabe N; Mine T; Kondo T; Scanlon KJ; Ueyama Y
    Int J Oncol; 2002 Nov; 21(5):1021-6. PubMed ID: 12370750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cell signaling and CDDP resistance].
    Masumoto N; Nakano S
    Gan To Kagaku Ryoho; 1997 Feb; 24(4):424-30. PubMed ID: 9063479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribozyme-targeting procathepsin D and its effect on invasion and growth of breast cancer cells: an implication in breast cancer therapy.
    Vashishta A; Ohri SS; Proctor M; Fusek M; Vetvicka V
    Int J Oncol; 2007 May; 30(5):1223-30. PubMed ID: 17390025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of proteasome alpha-subunit PSMA7 in hepatitis C virus internal ribosome entry site-mediated translation.
    Krüger M; Beger C; Welch PJ; Barber JR; Manns MP; Wong-Staal F
    Mol Cell Biol; 2001 Dec; 21(24):8357-64. PubMed ID: 11713272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-MDR1 ribozymes.
    Huesker M; Folmer Y; Schneider M; Fulda C; Blum HE; Hafkemeyer P
    Hepatology; 2002 Oct; 36(4 Pt 1):874-84. PubMed ID: 12297834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
    Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
    Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors.
    Pavco PA; Bouhana KS; Gallegos AM; Agrawal A; Blanchard KS; Grimm SL; Jensen KL; Andrews LE; Wincott FE; Pitot PA; Tressler RJ; Cushman C; Reynolds MA; Parry TJ
    Clin Cancer Res; 2000 May; 6(5):2094-103. PubMed ID: 10815937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligonucleotide scanning of native mRNAs in extracts predicts intracellular ribozyme efficiency: ribozyme-mediated reduction of the murine DNA methyltransferase.
    Scherr M; Reed M; Huang CF; Riggs AD; Rossi JJ
    Mol Ther; 2000 Jul; 2(1):26-38. PubMed ID: 10899825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.